Key facts
- Convalife Pharmaceuticals’s last known valuation is $444.6M (Jul 2025).
- It has raised $59.8M; the latest was IPO in Aug 2025.
- Notable investors include Optics Valley Financial Holdings Group, Fujian Shangrun Investment Management, Beijing Chuangye Letu Technology Group, Chengrong Investment, Hiway Capital — 12 tracked in total.
- Status: In IPO Registration.
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Convalife Pharmaceuticals
- ·The full record, as it builds
Funding rounds
No funding rounds for Convalife Pharmaceuticals are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Convalife Pharmaceuticals
Researcher and developer of innovative drugs focused on oncology treatments. The company focuses on antibody biopharmaceuticals and small molecule drug in tumor disease field, aiming to provide cancer patients with treatment options.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2015
- Employees
- 67
- Website
- convalife.com/
- Ownership
- In IPO Registration
Convalife Pharmaceuticals doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Convalife Pharmaceuticals shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Convalife Pharmaceuticals in its N-PORT filings yet. We sweep new filings monthly.